Thousands of men with prostate cancer in England will be offered a new, highly targeted radiotherapy on the NHS, slashing their required doses from over 20 to just five.
Stereotactic radiotherapy (SABR) is an effective, focused treatment that delivers higher radiation doses in fewer sessions, reducing side effects and cutting the risk of tumour growth or spread. Beams are directed from different angles, sparing healthy tissue.
